Abstract
Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Infectious Disorders - Drug Targets
Title: Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein
Volume: 12 Issue: 1
Author(s): Catherine Tamalet, Erwann P. Loret, Grant R. Campbell, Stephen A. Spector, Philippe Brouqui, Andreas Stein, Francoise Dignat-George, Pascale Paul, Corinne Brunet, Sonia Mediouni, Herve Moreau, Malika Mokhtari, Herve Tissot-Dupont, Catherine Dhiver, Isabelle Ravaux, Gilbert Baillat and Albert Darque
Affiliation:
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Abstract: Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Export Options
About this article
Cite this article as:
Tamalet Catherine, P. Loret Erwann, R. Campbell Grant, A. Spector Stephen, Brouqui Philippe, Stein Andreas, Dignat-George Francoise, Paul Pascale, Brunet Corinne, Mediouni Sonia, Moreau Herve, Mokhtari Malika, Tissot-Dupont Herve, Dhiver Catherine, Ravaux Isabelle, Baillat Gilbert and Darque Albert, Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein, Infectious Disorders - Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187152612798994939
DOI https://dx.doi.org/10.2174/187152612798994939 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Probiotics in the Management of Crohn's disease and Ulcerative Colitis
Current Pharmaceutical Design From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Kinetic Analysis of the Cleavage of Human Protease-Activated Receptor-1 / 2 / 3 and 4 Using Quenched-Fluorescent Peptide Substrates
Protein & Peptide Letters Inhibition of MHC II Gene Transcription by Nitric Oxide and Antioxidants
Current Pharmaceutical Design Meet Our Editorial Board Member
Recent Patents on Regenerative Medicine Functional Genomics Approaches in Cancer Research
Current Genomics Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Resveratrol and Stroke: from Chemistry to Medicine
Current Neurovascular Research CB-12181, a New Azasugar-Based Matrix Metalloproteinase/Tumor Necrosis Factor-α Converting Enzyme Inhibitor, Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and Retinal Neovascularization in Vivo
Current Neurovascular Research Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability
Current Drug Metabolism Review of Theoretical Studies for Prediction of Neurodegenerative Inhibitors
Mini-Reviews in Medicinal Chemistry The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Oligomerization of G Protein-Coupled Receptors: Computational Methods
Current Medicinal Chemistry Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo
Mini-Reviews in Medicinal Chemistry Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic and Environmental Risk Factors in Hyperuricaemia and Common Gout
Current Rheumatology Reviews